Conference Call with Dishman Carbogen Amcis Management and Analysts on Q3FY22 Performance and Outlook. Listen to the full earnings transcript.
Pharmaceuticals company Dishman Carbogen Amcis declares Q3FY22 result: Net Revenue at Rs 5,620.8 mn in Q3 FY22 up by 20.0% YoY CRAMS revenue increased by 34.3% YoY primarily due to: CRAMS India revenue increased by 97.9% due to steady increase in operations from the manufacturing plants located in India. CRAMS - Switzerland, France & China revenue increased by 31.5% due to higher commercial revenue. Marketable Molecules revenue decreased by 15.9% YoY primarily due to: Carbogen Amcis BV revenue decreased by 15.6% due to lower supplies of Vitamin D analogues. Others revenue decreased by 16.2% due to lesser focus on the lower margin molecules. EBITDA Margin at 19.5% in Q3 FY22 compared to 13.4% in Q3 FY21 due to: Higher CRAMS revenue, which is a high margin business segment. Net Debt excluding lease liabilities was USD 122 mn as on December 30, 2021 (USD 101 mn as on September 30, 2021). Capital expenditure for Q3 FY22 was approximately USD 19.93 mn. Result PDF
Q2 & H1 FY22 RESULT HIGHLIGHTS: Net Revenue at Rs 4,589.0 mn in Q2 FY22 up by 4.4% YoY CRAMS revenue remained flat increasing by 0.3% YoY primarily due to: CRAMS India revenue increased by 560.7% due to resumption of servicing of CRAMS orders after clearances received from customers CRAMS - Switzerland, France & China revenue decreased by 11.8% due to deferment of supply of certain commercial products already produced to the next quarter according to the customer requirements. Marketable Molecules revenue increased 19.9% YoY primarily due to Carbogen Amcis BV revenue increased by 36.3% due to increase in demand for cholesterol and Vitamin D analogues globally. EBITDA Margin increased to 21.6% in Q2 FY22 due to: CRAMS India registering significant growth in the high margin CRAMS business. Carbogen Amcis AG maintaining healthy margins at 20% Carbogen Amcis UK margins increased due to supply of higher value intermediates and starting materials. Net Debt excluding lease liabilities was USD 101 mn as on September 30, 2021 (USD 101 mn as on June 30, 2021). Capital expenditure for H1 FY22 was approximately USD 31.85 mn, which majorly includes capex at Swiss and French sites. Result PDF